Company / Financials
Theriva Biologics, Inc. Financials
FY2011-FY2011 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$2.6M
FY2011
Net Income
-$1.7M
FY2011
Profit Margin
-65.5%
FY2011 · net income / revenue
ROE
-48.3%
FY2011 · return on equity
Total Assets
$4.1M
FY2011
Total Debt
-
FY2011
Equity
$3.5M
FY2011
ROA
-41.6%
FY2011 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.80 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$2.6MNet Income HistoryProfit after all expenses and taxes-$1.7MSG&A Expense HistorySelling, general, and administrative expenses$2.1MR&D Expense HistoryResearch and development spending$1.6MEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.08Shares Outstanding HistoryWeighted average diluted shares outstanding23.3MTotal Assets HistoryTotal value of all assets owned$4.1MShareholders' Equity HistoryTotal assets minus total liabilities$3.5MCurrent Assets HistoryAssets expected to be converted to cash within one year$3.5MCurrent Liabilities HistoryObligations due within one year$500.0K